GW&K Investment Management LLC boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 575.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 123,611 shares of the company's stock after acquiring an additional 105,316 shares during the quarter. GW&K Investment Management LLC owned about 0.42% of Krystal Biotech worth $41,110,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Private Advisor Group LLC bought a new position in shares of Krystal Biotech during the 3rd quarter valued at about $444,000. Global Retirement Partners LLC grew its stake in shares of Krystal Biotech by 38.3% in the 3rd quarter. Global Retirement Partners LLC now owns 718 shares of the company's stock worth $239,000 after purchasing an additional 199 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in shares of Krystal Biotech by 27.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 8,208 shares of the company's stock worth $2,730,000 after purchasing an additional 1,750 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Krystal Biotech by 12.4% in the 3rd quarter. HighTower Advisors LLC now owns 2,394 shares of the company's stock worth $796,000 after purchasing an additional 265 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in shares of Krystal Biotech by 49.0% in the 3rd quarter. Hantz Financial Services Inc. now owns 693 shares of the company's stock worth $230,000 after purchasing an additional 228 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Krystal Biotech
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares in the company, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company's stock.
Krystal Biotech Trading Down 2.3%
KRYS stock opened at $308.57 on Friday. Krystal Biotech, Inc. has a one year low of $203.35 and a one year high of $382.54. The firm has a 50-day moving average of $322.48 and a two-hundred day moving average of $310.42. The firm has a market capitalization of $9.14 billion, a PE ratio of 40.42 and a beta of 0.56.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The company had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 7.74 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. Royal Bank Of Canada reduced their target price on shares of Krystal Biotech from $400.00 to $375.00 and set an "outperform" rating for the company in a report on Tuesday, November 3rd. William Blair raised Krystal Biotech to a "strong-buy" rating in a report on Wednesday, September 23rd. HC Wainwright reaffirmed a "buy" rating and issued a $361.00 price target on shares of Krystal Biotech in a report on Thursday, October 15th. The Goldman Sachs Group began coverage on Krystal Biotech in a research report on Thursday, September 24th. They set a "buy" rating and a $441.00 price objective for the company. Finally, Zacks Research downgraded Krystal Biotech from a "hold" rating to a "strong sell" rating in a research report on Friday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $375.00.
Read Our Latest Stock Analysis on Krystal Biotech
Krystal Biotech Company Profile
(
Free Report)
Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients' cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin's structure.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.